Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Metabolism and Bioavailability of Vicadrostat
NCT05515588Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vicadrostat in chronic kidney disease (CKD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Fraction of [14C] radioactivity excreted into urine up to 22 days, Fraction of [14C] radioactivity excreted into feces up to 22 days and 2 more. Started Sep 2022; status: completed.
02
Drugs
vicadrostat
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05515588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05515588.